Antibody-mediated Rejection Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Antibody-mediated Rejection Market is segmented By Treatment (Plasma Exchange, IVIG, Complement Inhibitors, Proteasome Inhibitors), By Drugs in Development (Clazakizumab, Imlifidase), By Therapeutic Approach (Monoclonal Antibodies, Complement Inhibitors), By Patient Type (Pre-sensitized Transplant Recipients, Acute AMR Patients), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned.
Antibody-mediated Rejection Market Size
Market Size in USD
CAGR12.64%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 12.64% |
| Market Concentration | High |
| Major Players | CSL Behring, Hansa Biopharma AB, Viela Bio, Janssen Biotech, Pfizer |
please let us know !
Antibody-mediated Rejection Market Analysis
The antibody-mediated rejection market is estimated to be valued at USD 126.5 Mn in 2024 and is expected to reach USD 291.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.64% from 2024 to 2031. The market is mainly driven by increasing solid organ transplant procedures globally along with rising investments in development of novel therapeutics for treatment of antibody-mediated rejection post-transplant.